The Regulation of Heterogeneous Cellular Population in Cancers: Single-Cell Analysis

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (30 December 2022) | Viewed by 3496

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China
Interests: NGS; cancer genomics; scRNA-seq; single-cell sequencing; liquid_biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a common fatal human disease, and it often has a high degree of both intra- and inter-tumor heterogeneity. Moreover, it involves a complex tumor microenvironment, which consists of different immune and stromal components that interact with malignant cells to shape the favorable cellular and molecular landscapes that support tumor development. Traditional analytical strategies have their inherent limitations, and the emergence of single-cell sequencing enables comprehensive investigations to be conducted in an unprecedented level of detail. Given the merits of single-cell sequencing approaches in the study of human cancer, an increasing number of studies are adopting this strategic method.

For this Special Issue, we are focusing on various aspects of single-cell investigations in cancer, ranging from basic to translational perspectives. This Special Issue will act as a research platform, bringing together a collection of original research articles, reviews, and communications covering any topics related to single-cell investigations of cancer, including but not limited to, tumor heterogeneity, cellular and molecular landscapes, cell–cell interactions, mechanistic delineation, animal models and/or biomarker discovery.

Dr. Daniel Wai Hung Ho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • single-cell investigation
  • heterogeneity
  • cell-cell interaction
  • mechanism

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1642 KiB  
Review
Single-Cell Analysis of Primary Liver Cancer in Mouse Models
by Tina Suoangbaji, Vanilla Xin Zhang, Irene Oi-Lin Ng and Daniel Wai-Hung Ho
Cells 2023, 12(3), 477; https://doi.org/10.3390/cells12030477 - 1 Feb 2023
Cited by 1 | Viewed by 3232
Abstract
Primary liver cancer (PLC), consisting mainly of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is one of the major causes of cancer-related mortality worldwide. The curative therapy for PLC is surgical resection and liver transplantation, but most PLCs are inoperable at diagnosis. Even after surgery, [...] Read more.
Primary liver cancer (PLC), consisting mainly of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is one of the major causes of cancer-related mortality worldwide. The curative therapy for PLC is surgical resection and liver transplantation, but most PLCs are inoperable at diagnosis. Even after surgery, there is a high rate of tumor recurrence. There is an unmet clinical need to discover more effective treatment options for advanced PLCs. Pre-clinical mouse models in PLC research have played a critical role in identifying key oncogenic drivers and signaling pathways in hepatocarcinogenesis. Furthermore, recent advances in single-cell RNA sequencing (scRNA-seq) have provided an unprecedented degree of resolution in such characterization. In this review, we will summarize the recent studies that utilized pre-clinical mouse models with the combination of scRNA-seq to provide an understanding of different aspects of PLC. We will focus particularly on the potentially actionable targets regarding the cellular and molecular components. We anticipate that the findings in mouse models could complement those in patients. With more defined etiological background, mouse models may provide valuable insights. Full article
Show Figures

Figure 1

Back to TopTop